- Home
- / Ikena Oncology
Ikena Oncology
Stock Price
$4.6
2023-09-22
Market Capitalization
$200.4 M
2023-09-22
Revenue
$15.6 M
FY, 2022
Ikena Oncology Summary
Company Summary
- Overview
- Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. It develops programs across distinct molecular targets and biologic pathways modulating both the immune system and the tumor.
- Type
- Public
- Status
- Active
- Founded
- 2016
- HQ
- Boston, MA, US | view all locations
- Website
- https://ikenaoncology.com
- Cybersecurity rating
Table of Contents
Key People
Douglas R. Carlson, Chief Operating Officer & EVP, Finance
Jeffrey Ecsedy, Chief Scientific Officer
Sergio Santillana, Chief Medical Officer
Ikena Oncology Financials
Summary Financials
- Revenue (Q2, 2023)
- $2.0M
- Net income (Q2, 2023)
- ($17.1M)
- Cash (Q2, 2023)
- $70.9M
- EBIT (Q2, 2023)
- ($18.5M)
- Enterprise value
- $141.6M